Chrome Extension
WeChat Mini Program
Use on ChatGLM

Differential Immunogenicity of Homologous Versus Heterologous Boost in Ad26.COV2.S Vaccine Recipients.

Med (MED)(2022)

Duke NUS Med Sch | Queen Mary Univ London

Cited 22|Views15
Abstract
Protection offered by COVID-19 vaccines wanes over time, requiring an evaluation of different boosting strategies to revert such a trend and enhance the quantity and quality of Spike-specific humoral and cellular immune responses. These immunological parameters in homologous or heterologous vaccination boosts have thus far been studied for mRNA and ChAdOx1 nCoV-19 vaccines, but knowledge on individuals who received a single dose of Ad26.COV2.S is lacking. We studied Spike-specific humoral and cellular immunity in Ad26.COV2.S vaccinated individuals (n=55) who were either primed with Ad26.COV2.S only (n=13), or boosted with a homologous (Ad26.COV2.S, n=28) or heterologous (BNT162b2, n=14) second dose. We compared our findings with the results found in individuals vaccinated with a single (n=16) or double (n=44) dose of BNT162b2. We observed that a strategy of heterologous vaccination enhanced the quantity and breadth of both, Spike-specific humoral and cellular immunity in Ad26.COV2.S vaccinated. In contrast, the impact of homologous boost was quantitatively minimal in Ad26.COV2.S vaccinated and Spike-specific antibodies and T cells were narrowly focused to the S1 region. Although a direct association between quantity and quality of immunological parameters and in vivo protection has not been demonstrated, the immunological features of Spike-specific humoral and cellular immune responses support the utilization of a heterologous strategy of vaccine boost in individuals who received Ad26.COV2.S vaccination.
More
Translated text
Key words
COVID-19,vaccines,antiviral immunity,Adenovirus vector,heterologous immunity
PDF
Bibtex
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
  • Pretraining has recently greatly promoted the development of natural language processing (NLP)
  • We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
  • We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
  • The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
  • Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Try using models to generate summary,it takes about 60s
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper

要点】:该论文探讨了Ad26.COV2.S疫苗接种者接受同源或异源增强针后,针对Spike蛋白的免疫反应差异,发现异源增强针能显著提高免疫应答的量和广度。

方法】:通过对比Ad26.COV2.S疫苗接种者接受同源(Ad26.COV2.S)或异源(BNT162b2)增强针后的免疫参数,以及与单剂或双剂BNT162b2疫苗接种者的免疫反应差异,评估免疫应答的变化。

实验】:在55名Ad26.COV2.S疫苗接种者中(其中13名仅接受Ad26.COV2.S,28名接受同源增强,14名接受异源增强),研究了Spike特异性体液和细胞免疫,并与16名单剂和44名双剂BNT162b2疫苗接种者的结果进行比较,发现异源增强策略显著增强了免疫应答的量和广度。